Madrid, Spain, and Heidelberg, Germany, October 04, 2016 – SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today announced that the Company has presented its revolutionary TruePrime™ technology at two renowned scientific conferences.
From September 14th – 16th, the SINGLE CELL GENOMICS MEETING was held in Cambridge, United Kingdom. Single cell genomics is a revolutionary technology transforming many fields of biological research, including immunology and cancer. Today, many different applications (e.g. single cell genome sequencing, single cell transcriptomics, and various single cell epigenetic profiling approaches) are being used by researchers to characterize the genetic and functional properties of individual cells under native conditions, leading to numerous experimental and clinical opportunities.
During the meeting, cutting edge topics and questions were raised. Questions discussed included: ”Which technologies are going to set the standard in the field?”, “How can single cell genomics and epigenomics technologies be integrated in workflows?” or “What are the immediate implications for immunology, cancer research and germ cells?”.
For SYGNIS, this conference was one of the key events to promote its technology in the single cell market, one of the most important markets for the Company. SYGNIS’ TruePrime™ products provide superior advantages over current technologies and solve most of the problems that researchers are facing in single cell analysis today. SYGNIS introduced and promoted its TruePrime™ technology as key new technology for DNA amplification to the scientific community in a poster presentation.
“It is part of our strategy to present our innovative TruePrime technology at all high level meetings, with the goal of becoming the new gold standard for Whole Genome Amplification, targeting Next Generation Sequencing users, and consequently the NGS market”, commented Pilar de la Huerta, Co-CEO and CFO of SYGNIS AG. “As a result of our marketing activities, we receive a lot of positive feedback from the scientific community. This makes us very confident that we can accelerate our sales as these types of tools are a key element for researchers, moreover the NGS market is growing at a double digit rate.”
SYGNIS AG also presented at the AGBT (Advances in Genome Biology and Technology) PRECISON HEALTH MEETING. The conference took place in Arizona, USA, from September 22nd – 24th.
Since 2000, the AGBT meeting has been recognized worldwide among researchers as the preeminent conference where scientists and experts in the fields of genomics and biology meet to collaborate, advance research, educate and explore new opportunities. This meeting aims to enable contact among pioneering researchers and developers of genome technologies to first movers in healthcare who are establishing cutting edge standard of care applications of genome technology in every day clinical practice. At this event, SYGNIS presented and promoted its TruePrime™ technology as key new technology for DNA amplification to the scientific community in a poster presentation.
SYGNIS AG
Pilar de la Huerta
Co-CEO/CFO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com
MC Services AG
Raimund Gabriel
Managing Partner
Phone: +49 89 210228 30
Email: raimund.gabriel@mc-services.eu
About SYGNIS AG: www.sygnis.com
SYGNIS AG is specialized in the development and the commercialization of proprietary technologies and offers a wide range of different commercial products addressing key challenges in molecular biology. With the acquisition of Expedeon Holdings, Ltd. based in Cambridge, UK, SYGNIS has added a complementary proteomic product portfolio. Resulting from this significant expansion, SYGNIS’ product portfolio now covers the entire workflow of molecular biology. The products are sold through a direct sales force and several distribution partners in Europe, the US and Asia. SYGNIS AG has offices in Germany, Spain and the UK, production sites in the UK and the US as well as sales offices in Asia. The company is listed on the German Stock Exchange in Frankfurt in the Prime Standard segment (Ticker: LIO1; ISIN: DE000A1RFM03).
